Dronagi 35 Agimexpharm treat and prevent osteoporosis (1 blister x 4 tablets)

RISDEDRONAT directly acts on the skeleton, and thus helps the bones are less likely to be broken.

risesronat combines with hydroxyapatite in the bone and acts as an anti -bone destruction agent.

At the cell level, Riseadronate inhibits the cell cancel. Normally, the cell canvel stick to the bone surface, but shows evidence of reducing bone destruction activity (for example, no rippling banks).

Morology test on mice, dogs and mice shows that Riseadronat treatment reduces bone movement (frequency of operation, that is, the proportion of bone restructuring positions is activated) and bone destruction in restructuring positions.

In clinical and clinical research and clinical research, the biochemical imprint of the bone transfer within 1 month and reaches the maximum of 3-6 months.

Dynamic pharmacokinetics

Absorption: After taken, the drug is absorbed relatively quickly (T max about 1 hour) and independent of the dose. The average bioavailability when taking tablets is 0.63% and reduces when sodium Riseadronate is taken with food. Born in men and women similarly.

Distribution: The volume of distribution in a state of stability is 6.3 liters/kg. About 24% of the drug is attached to plasma proteins.

Metabolism: There is no evidence of systemic metabolism for sodium Riseadronate.

Elimination: About half of the absorbed dose is excreted in the urine within 24 hours. The absorption drug is excreted in the form of unchanged in feces.

Notify the physician the unwanted effects when using the drug.

Be cautious when using

side effects in the gastrointestinal tract: Food and drink (except for normal water) and pharmaceuticals containing multi -chemotherapy cations (such as calcium, magnesium, iron or aluminum) can hinder the absorption of risesDronate, so it is not used at the same time when taking this medicine.

Therefore, it must be taken at at least 30 minutes before eating, taking or before taking the first medicine for the first day.

Some bisphosphonats, including riseadronat, can cause disorders in the gastrointestinal tract such as difficulty swallowing, esophagitis, gastritis, esophagus or gastrointestinal ulcer. So be cautious when taking this medication:

In patients with a history of esophageal disorders such as esophageal stenosis or esophageal belt slow or difficulty giving food through the esophagus.

In patients who cannot hold the vertical position for at least 30 minutes after taking the drug.

In patients with problems of the above gastrointestinal tract (including Barrett esophagus).

Doctors should remind patients to pay attention to adhere to the instructions for drug use to minimize the risk of the above side effects and alert the patient to stop taking the drug, report immediately to the doctor if there is a new or worse symptom.

Mineral metabolism: thoroughly treating blood calcium and bone metabolic and mineral metabolic disorders (for example, hyperthetic dysfunction, vitamin D deficiency) before starting treatment with RISEDRONAT. The addition of calcium and vitamin D is important for all patients, especially patients with paget disease with significant increase in bone rotation.

Glucocorticoid osteoporosis: Before starting to use riseadronat to treat and prevent osteoporosis caused by glucocorticoids, it is recommended to determine the status of sex steroid hormones of both men and women and consider the appropriate replacement.

Jaw bone necrosis: Jaw bone necrosis has also been reported in patients with osteoporosis bishosphonate.

Dental test with appropriate dental provision should be considered before bisphosphonate treatment in patients with risk factors (such as cancer, chemotherapy, radiation, corticosteroid, poor dental hygiene).

During treatment with bisphosphonate, patients should avoid invasive dental procedures (for example, tooth extraction, dental transplant). For patients with jaw bone necrosis while treating bisphosphonate, tooth surgery can worsen this condition. Patients who need dental procedures, stop treatment of bisphosphonate can reduce the risk of jaw bone necrosis. The suspension of bisphosphonate should be treated by a doctor and/ or a dental surgeon based on the assessment of the benefits/ risks of each patient.

Not typical femoral fractures: The typical femoral fracture has been reported with bisphosphonate therapy, mainly in patients who are treated for long -term osteoporosis. During the time patients treated with bisphosphonat, it should be advised to report any thigh pain, hip pain or groin pain and any patient with such symptoms must be assessed by the femoral fracture.

Patients with a typical crack should also be evaluated for symptoms and signs of fractures on the opposite limb. Stopping bisphosphonate treatment in patients suspected of not typical femoral fractures should be considered based on the risk/ benefit assessment of each patient.

Patients with renal failure: Riseadronate is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/minute).

The effect of the drug on the ability to drive and operate machinery

has not seen any adverse effects on the person who is driving and operating machinery.

Use drugs for women during pregnancy and lactation

Do not use this drug for pregnant or lactating women. Only use when benefits bring higher risk to fetus or breastfeeding.

Medicinal interaction

Take taken simultaneously with drugs containing polymer chemotherapy (such as calcium, magnesium, iron and aluminum) can hinder the absorption of Riseadronat. These drugs should be taken at another time during the day without coinciding with drinking rises.

Can use Riseadronat simultaneously with estrogen supplements if considered carefully.

Riseadronate is not metabolized in the body, does not cause P450 enzyme and is less attached to protein.

Acetylsalicylic or NSAID acid: Among those who regularly use acetylsalicylic or NSAID acid (3 days or more per week) The ratio of gastrointestinal effects in patients treated with Risedronate is similar to the control patients (using Placebo).